Clearmind Medicine Files International Patent Application for Novel Combination Therapy

SEC Filing 6-K (0001213900-25-068959)

Clearmind Medicine Inc. has filed an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy targeting weight loss and fatty liver disease. The therapy combines MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA) to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Obesity affects over 890 million people globally, and non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the global adult population. Clearmind believes this therapy offers a safe and effective alternative, leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties. The patent filing is part of Clearmind's collaboration with SciSparc Ltd. The company aims to bring meaningful innovation to areas with high unmet medical needs.